Auf dieser Seite
KLRS Kalaris Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 11, 2026
$2,70
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$2,5152-Wochen-Tief
$11,5552-Wochen-Hoch
Marktkapitalisierung (MRQ)
$64M
P/E
-0.9
EPS
$-2.85
Ihre Abzeichen
52W-Spanne
$3–$12
Analystenbewertung
STRONG BUY
Kursziel
$19
P/E
-0.9
ROE
-65.8%
Nettogewinnmarge
·
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
KLRS Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$2.70
Marktkapitalisierung (MRQ)
$64M
P/E
-0.9
EPS
$-2.85
ROE
-65.8%
52W-Spanne
$3–$12
KLRS Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 16. Januar 2025 | 1-for-23 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz·2019-12-31 → 2019-12-31
EPS$-2.852021-12-31 → 2025-12-31
Freier Cashflow$-39M2020-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | KLRS | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -0.95-Jahres-Durchschnitt ≈-33.2 | ≈-33.2 | · | · | |
| K/B (MRQ) | 1.15-Jahres-Durchschnitt ≈16.0 | ≈16.0 | 1.3 | Teurer | |
| Price / FCF (Kurs / FCF) | -1.6 | · | · | · | |
| Price / Cash Flow (Kurs / Cashflow) | -1.65-Jahres-Durchschnitt ≈-24.4 | ≈-24.4 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 0.85-Jahres-Durchschnitt ≈45.1 | ≈45.1 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | KLRS | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| ROA | -67.9%5-Jahres-Durchschnitt ≈-61.8% | ≈-61.8% | -69.2% | Im Einklang | |
| ROE | -65.8%5-Jahres-Durchschnitt ≈-184.8% | ≈-184.8% | -72.9% | Im Einklang | |
| ROIC | -58.6%5-Jahres-Durchschnitt ≈-82.4% | ≈-82.4% | -70.9% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | KLRS | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 11.05-Jahres-Durchschnitt ≈12.9 | ≈12.9 | 3.3 | Starke Liquidität | |
| Quick Ratio | 12.15-Jahres-Durchschnitt ≈12.7 | ≈12.7 | 3.2 | Starke Liquidität | |
| Interest Coverage (Zinsdeckungsgrad) | -32.0 | · | -32.0 | Im Einklang |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-21.7%
Nächster Bericht
Nov 10, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 19, 2026 | $-0.48 | $-0.50 | 4.9% |
| 31. März 2026 | Mai 20, 2026 | $-0.46 | $-0.53 | 13.8% |
| 31. Dezember 2025 | $-0.51 | $-0.54 | 5.9% | |
| 30. September 2025 | $-0.64 | $-0.67 | 3.9% | |
| 30. Juni 2025 | $-0.61 | $-0.53 | -15.0% | |
| 31. März 2025 | $-2.52 | $-0.79 | -218.8% | |
| 30. Juni 2024 | $-1.15 | $-2.46 | 53.3% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $165.0K | |
| R&D Expense | $31M | $45M | $133M | $119M | $121M | $50M | $16M | |
| SG&A Expense | $15M | $7M | $48M | $52M | $49M | $22M | $11M | |
| Operating Expenses | $46M | $52M | $200M | $171M | $170M | $71M | $27M | |
| Operating Income | $-46M | $-52M | $-200M | $-171M | $-170M | $-71M | $-27M | |
| Interest Expense | $1M | $3M | · | · | · | · | · | |
| Interest Income | · | $5M | $6M | $2M | $1M | $1M | $2M | |
| Other Non-op | $3M | $188.0K | $4M | $351.0K | $-2M | $195.0K | $797.0K | |
| Pretax Income | $-43M | $-69M | $-191M | $-169M | $-171M | $-70M | $-24M | |
| Income Tax | $0 | $0 | $-126.0K | $-265.0K | $1M | · | · | |
| Net Income | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | $-24M | |
| EPS (Basic) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| EPS (Diluted) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| Shares (Basic) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| Shares (Diluted) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| EBITDA | $-46M | $-65M | $-200M | $-170M | · | $-71M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $98M | $2M | $90M | $106M | $202M | $123M | $61M | |
| Short-term Investments | $20M | $0 | $94M | $128M | $46M | $234M | $65M | |
| Prepaid Expense | $827.0K | $967.0K | $3M | $7M | $5M | $5M | $676.0K | |
| Current Assets | $119M | $3M | $188M | $243M | $253M | $361M | $127M | |
| PP&E (Net) | · | · | · | $930.0K | $2M | $812.0K | $350.0K | |
| PP&E (Gross) | · | · | $2M | $2M | $2M | $904.0K | $369.0K | |
| Accum. Depreciation | · | · | · | $1M | $281.0K | $92.0K | $19.0K | |
| Other Non-current Assets | $953.0K | $410.0K | $122.0K | $612.0K | $1M | · | · | |
| Total Assets | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Accounts Payable | $1M | $2M | $7M | $3M | $8M | $963.0K | $630.0K | |
| Accrued Liabilities | · | $5M | $10M | $14M | $20M | $8M | $5M | |
| Current Liabilities | $10M | $25M | $28M | $24M | $38M | $12M | $9M | |
| Capital Leases | $1M | $0 | $17M | $28M | $23M | $5M | $9M | |
| Total Liabilities | $43M | $57M | $45M | $53M | $61M | $18M | $18M | |
| Common Stock | $2.0K | $0 | $0 | $9.0K | $7.0K | $7.0K | · | |
| Paid-in Capital | $239M | $20M | $802M | $691M | $522M | $478M | $4M | |
| Retained Earnings | $-160M | $-117M | $-656M | $-466M | $-297M | $-125M | $-55M | |
| AOCI | $6.0K | $0 | $-62.0K | $-468.0K | $-155.0K | $-112.0K | $68.0K | |
| Stockholders' Equity | $79M | $-97M | $-45M | $225M | $225M | $353M | $-52M | |
| Liabilities + Equity | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Shares Outstanding | 22,902,418 | 1,356,431 | 4,962,997 | 93,093,243 | 63,565,886 | 61,931,255 | 2,099,740 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $398.0K | $723.0K | $189.0K | $73.0K | $19.0K | |
| Stock-based Comp | $2M | $895.0K | $41M | $41M | $44M | $9M | $3M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | $10M | · | · | · | · | · | |
| Other Non-cash | · | · | $25M | $-15M | · | $-529.0K | · | |
| Operating Cash Flow | $-38M | $-21M | $-124M | $-142M | $-106M | $-61M | $-20M | |
| CapEx | $200.0K | · | · | · | $26.0K | $235.0K | $339.0K | |
| Investing Cash Flow | $-20M | $95M | $38M | $-80M | $186M | $-169M | $-65M | |
| Stock Issued | $42M | · | · | $126M | · | · | · | |
| Net Stock Activity | $42M | · | · | $126M | · | · | · | |
| Financing Cash Flow | $155M | $19M | $70M | $127M | $232.0K | $292M | $121M | |
| Net Change in Cash | $97M | $-2M | $-16M | $-96M | $80M | $62M | $36M | |
| Taxes Paid | $0 | $0 | $220.0K | $613.0K | · | · | · | |
| Free Cash Flow | $-39M | · | · | · | · | $-61M | · | |
| Levered FCF | $-40M | · | · | · | · | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| ROA | -67.9% | -38.0% | -81.4% | -59.9% | · | -27.4% | · | |
| ROE | -65.8% | -491.2% | -111.6% | -70.6% | · | -19.2% | · | |
| ROIC | -58.6% | -57.8% | -137.0% | -76.1% | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.2 | 22.6 | 6.6 | 10.0 | · | 29.4 | · | |
| Quick Ratio | 12.1 | 22.6 | 6.5 | 9.6 | · | 29.0 | · | |
| Interest Coverage | -32.0 | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.44 | $22.48 | $1.28 | $2.41 | · | $5.70 | · | |
| Cash Flow / Share | $-2.51 | $-13.52 | $-1.20 | $-1.85 | · | · | · | |
| Cash / Share | $4.28 | $23.47 | $0.79 | $1.14 | · | $1.98 | · | |
| EPS (TTM) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | · | |
| Market Cap | $193M | $49M | $1.79B | $10.98B | · | $54.75B | · | |
| P/E | -3.0 | -0.2 | -0.4 | -53.6 | -108.6 | · | · | |
| P/B | 2.5 | 0.4 | 12.2 | 48.9 | · | 155.1 | · | |
| P / Tangible Book | 2.5 | · | · | 48.9 | 84.0 | 155.1 | · | |
| P / Cash Flow | -5.0 | -0.7 | -14.3 | -77.3 | · | -900.4 | · | |
| P / FCF | -5.0 | · | · | · | · | -896.9 | · | |
| Earnings Yield | -33.8% | -535.9% | -269.1% | -1.9% | -0.92% | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $9M | $8M | $7M | $9M | $8M | $6M | $4M | $36M | $3M | $2M | $33M | $34M | $35M | $31M | $28M | $30M | |
| SG&A Expense | $3M | $4M | $4M | $4M | $4M | $4M | $3M | $2M | $976.0K | $602.0K | $10M | $13M | $12M | $13M | $12M | $13M | |
| Operating Expenses | $12M | $12M | $11M | $13M | $12M | $10M | $7M | $38M | $4M | $3M | $62M | $47M | $47M | $43M | $40M | $43M | |
| Operating Income | $-12M | $-12M | $-11M | $-13M | $-12M | $-10M | $-7M | $-38M | $-4M | $-3M | $-62M | $-47M | $-47M | $-43M | $-40M | $-43M | |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1M | $1M | $815.0K | $499.0K | $78.0K | · | · | · | · | · | · | |
| Interest Income | · | · | · | · | · | · | · | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $898.0K | $668.0K | |
| Other Non-op | $871.0K | $977.0K | $803.0K | $847.0K | $906.0K | $193.0K | $64.0K | $31.0K | $66.0K | $27.0K | $1M | $1M | $521.0K | $723.0K | $986.0K | $210.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | $-60M | $-44M | $-45M | · | $-39M | $-42M | |
| Income Tax | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-126.0K | $0 | $0 | $0 | $-415.0K | $0 | |
| Net Income | $-12M | $-11M | $-10M | $-12M | $-11M | $-10M | $-22M | $-38M | $-6M | $-3M | $-60M | $-44M | $-45M | $-41M | $-38M | $-42M | |
| EPS (Basic) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| EPS (Diluted) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| Shares (Basic) | 23,797,306 | 23,723,618 | · | 18,701,708 | 18,701,286 | 4,053,140 | · | 1,352,265 | 1,325,706 | 1,312,552 | · | 113,894,188 | 94,625,837 | 93,303,672 | · | 84,948,837 | |
| Shares (Diluted) | 23,797,306 | 23,723,618 | · | 18,701,708 | 18,701,286 | 4,053,140 | · | 1,352,265 | 1,325,706 | 1,312,552 | · | 113,894,188 | 94,625,837 | 93,303,672 | · | 84,948,837 | |
| EBITDA | $-12M | $-12M | · | $-13M | $-12M | $-10M | · | $-6M | $-8M | $-32M | · | $-47M | $-47M | $-43M | · | $-43M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $34M | $98M | $42M | $88M | $101M | $2M | $117M | $105M | $86M | $90M | $96M | $197M | $116M | $106M | $124M | |
| Short-term Investments | $50M | $63M | $20M | $35M | · | · | $0 | $5M | $25M | $54M | $94M | $118M | $50M | $87M | $128M | $140M | |
| Prepaid Expense | $2M | $861.0K | $827.0K | $1M | $3M | $1M | $967.0K | $626.0K | $230.0K | $771.0K | $3M | $6M | $5M | $7M | $7M | $6M | |
| Current Assets | $96M | $98M | $119M | $78M | $92M | $102M | $3M | $123M | $130M | $141M | $188M | $220M | $253M | $212M | $243M | $272M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | $673.0K | $759.0K | $844.0K | $930.0K | $943.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | · | |
| Other Non-current Assets | $2M | $2M | $953.0K | $976.0K | $691.0K | $410.0K | $410.0K | · | · | · | $122.0K | $1M | $684.0K | $490.0K | $612.0K | $734.0K | |
| Total Assets | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Accounts Payable | $1M | $905.0K | $1M | $494.0K | $4M | $2M | $2M | $51.0K | $110.0K | $765.0K | $7M | $4M | $5M | $4M | $3M | $5M | |
| Accrued Liabilities | · | · | · | · | · | · | · | $1M | $2M | $5M | $10M | $16M | $17M | $12M | $14M | $14M | |
| Current Liabilities | $9M | $8M | $10M | $6M | $8M | $7M | $25M | $1M | $2M | $8M | $28M | $33M | $31M | $25M | $24M | $21M | |
| Capital Leases | $1M | $1M | $1M | $1M | · | · | $0 | · | $8M | $16M | $17M | $20M | $23M | $26M | $28M | $20M | |
| Total Liabilities | $42M | $41M | $43M | $39M | $40M | $39M | $57M | $1M | $11M | $24M | $45M | $53M | $54M | $51M | $53M | $40M | |
| Common Stock | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $0 | $11.0K | $11.0K | $11.0K | $0 | $11.0K | $11.0K | $9.0K | $9.0K | $9.0K | |
| Paid-in Capital | $240M | $239M | $239M | $192M | $191M | $191M | $20M | $818M | $813M | $807M | $802M | $792M | $782M | $701M | $691M | $681M | |
| Retained Earnings | $-182M | $-171M | $-160M | $-150M | $-138M | $-127M | $-117M | $-697M | $-693M | $-686M | $-656M | $-596M | $-552M | $-507M | $-466M | $-428M | |
| AOCI | $-73.0K | $-49.0K | $6.0K | $6.0K | · | · | $0 | $-134.0K | $-139.0K | $-138.0K | $-62.0K | $-200.0K | $-225.0K | $-301.0K | $-468.0K | $-563.0K | |
| Stockholders' Equity | $58M | $69M | $79M | $42M | $53M | $64M | $-97M | $121M | $120M | $120M | $146M | $195M | $229M | $194M | $225M | $253M | |
| Liabilities + Equity | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Shares Outstanding | 23,804,981 | 22,992,291 | 22,902,418 | 18,702,418 | 18,702,418 | 18,702,418 | 1,356,431 | 115,438,119 | 115,312,411 | 114,881,765 | 4,962,997 | 113,966,594 | 113,716,018 | 93,427,990 | 93,093,243 | 92,640,109 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | $141.0K | $86.0K | $85.0K | $86.0K | $86.0K | $85.0K | |
| Stock-based Comp | $644.0K | $580.0K | $333.0K | $638.0K | $591.0K | $374.0K | $280.0K | $-10M | $-5M | $31.0K | $10M | $10M | $10M | $10M | $9M | $11M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | $0 | |
| Restructuring | · | · | · | · | · | · | · | $100.0K | $500.0K | $10M | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | · | · | · | · | $-1M | · | · | |
| Operating Cash Flow | $-11M | $-12M | $-7M | $-11M | $-13M | $-7M | $-8M | $43M | $36M | $-5M | $-31M | $-34M | $-27M | $-32M | $-32M | $-35M | |
| CapEx | · | · | $17.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $20M | $-50M | $15M | · | · | · | · | $20M | $30M | $40M | $25M | $-67M | $38M | $42M | $14M | $-39M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Financing Cash Flow | $-377.0K | $-2M | $48M | $0 | $0 | $107M | $8M | $12M | $5M | $7M | $11.0K | $0 | · | · | $292.0K | $126M | |
| Net Change in Cash | $9M | $-64M | $56M | $-46M | $-13M | $100M | $-274.0K | $-16M | $7M | $2M | $-6M | $-101M | $81M | $10M | $-18M | $53M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $-131.0K | $1.0K | · | · | $-390.0K | $0 |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -12.0% | -10.2% | · | -11.7% | -10.1% | -8.2% | · | -2.2% | -2.9% | -15.6% | · | -16.3% | -18.8% | -17.3% | · | -13.8% | |
| ROE | -20.8% | -16.4% | · | -14.6% | -13.1% | -11.1% | · | -2.6% | -3.5% | -19.3% | · | -19.7% | -23.4% | -21.4% | · | -16.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -24.0% | -20.6% | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.0 | 12.2 | · | 12.9 | 12.0 | 14.3 | · | 86.8 | 55.1 | 18.5 | · | 6.7 | 8.3 | 8.5 | · | 13.1 | |
| Quick Ratio | 10.7 | 12.0 | · | 12.7 | 11.6 | 14.1 | · | 86.3 | 54.9 | 18.4 | · | 6.5 | 8.1 | 8.1 | · | 12.7 | |
| Interest Coverage | · | · | · | · | · | -7.2 | · | · | · | · | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.42 | $2.98 | · | $2.24 | $2.84 | $3.42 | · | $1.05 | $1.04 | $1.05 | · | $1.71 | $2.01 | $2.07 | · | $2.73 | |
| Cash Flow / Share | · | $-0.49 | · | · | · | $-1.84 | · | · | · | $-0.39 | · | · | · | $-0.34 | · | · | |
| Cash / Share | $1.81 | $1.50 | · | $2.27 | $4.73 | $5.40 | · | $1.01 | $0.91 | $0.75 | · | $0.84 | $1.73 | $1.24 | · | $1.34 | |
| EPS (TTM) | $-0.66 | $-0.79 | · | $-20.52 | $-48.04 | $-51.69 | · | $-75.80 | $-48.03 | $-44.25 | · | $-1.63 | $-1.74 | $-1.95 | · | $-2.80 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-44M | $-44M | · | $-55M | $-82M | $-76M | · | $-107M | $-113M | $-153M | · | $-169M | $-167M | $-166M | · | $-189M | |
| Market Cap | $97M | $133M | · | $108M | $50M | $150M | · | $2.15B | $1.92B | $1.99B | · | $5.64B | $8.89B | $8.47B | · | $16.81B | |
| P/E | -6.2 | -7.3 | · | -0.3 | -0.1 | -0.2 | · | -0.2 | -0.3 | -0.4 | · | -30.3 | -44.9 | -46.5 | · | -64.8 | |
| P/B | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Tangible Book | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Cash Flow | · | -11.5 | · | · | · | -20.2 | · | · | · | -45.0 | · | · | · | -263.6 | · | · | |
| Earnings Yield | -16.2% | -13.7% | · | -355.0% | -1799.2% | -643.7% | · | -407.4% | -288.8% | -254.8% | · | -3.3% | -2.2% | -2.1% | · | -1.5% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Nettoergebnis | $-43M | $-69M | $-190M | $-169M | $-172M |
| Verwässerte EPS | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 12.2 | 22.6 | 6.6 | 10.0 | · |
| Quick Ratio | 12.1 | 22.6 | 6.5 | 9.6 | · |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-39M | · | · | · | · |
Institutionelle Eigentümer (13F) 57 Einreicher · $75.8M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
57
Gehaltener Wert
$75.8M
Neue Positionen
9
Geschlossene Positionen
11
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 9 (-6 vs. Vorquartal) | 11 (+4 vs. Vorquartal) | 18 (+2 vs. Vorquartal) | 9 (+2 vs. Vorquartal) | -548K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | $52.426.382 | 12.881.175 | 69,20% | Aktien |
| RTW INVESTMENTS, LP | $5.291.000 | 1.300.000 | 6,98% | Aktien |
| VANGUARD GROUP INC | $2.471.147 | 292.790 | 3,26% | Aktien |
| Alyeska Investment Group, L.P. | $2.330.836 | 572.687 | 3,08% | Aktien |
| Siren, L.L.C. | $1.773.698 | 435.798 | 2,34% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.622.758 | 398.712 | 2,14% | Aktien |
| Ikarian Capital, LLC | $1.465.201 | 360.000 | 1,93% | Aktien |
| UBS Group AG | $1.066.873 | 262.131 | 1,41% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $607.859 | 149.351 | 0,80% | Aktien |
| MARSHALL WACE, LLP | $566.549 | 139.201 | 0,75% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $464.287 | 114.037 | 0,61% | Aktien |
| Woodline Partners LP | $407.000 | 100.000 | 0,54% | Aktien |
| ADAR1 Capital Management, LLC | $407.000 | 100.000 | 0,54% | Aktien |
| WHI TRUST Co LLC | $396.797 | 97.493 | 0,52% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $395.457 | 97.164 | 0,52% | Aktien |
| CITADEL ADVISORS LLC | $389.792 | 95.772 | 0,51% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $375.502 | 92.261 | 0,50% | Aktien |
| Verdad Advisers, LP | $326.809 | 80.297 | 0,43% | Aktien |
| MORGAN STANLEY | $294.367 | 72.326 | 0,39% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $269.349 | 66.179 | 0,36% | Aktien |
| BlackRock, Inc. | $221.580 | 54.442 | 0,29% | Aktien |
| Fortis Capital Advisors, LLC | $162.800 | 40.000 | 0,21% | Aktien |
| Belpointe Asset Management LLC | $162.800 | 40.000 | 0,21% | Aktien |
| Pale Fire Capital SE | $161.278 | 39.626 | 0,21% | Aktien |
| Squarepoint Ops LLC | $157.814 | 38.775 | 0,21% | Aktien |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $132.275 | 32.500 | 0,17% | Aktien |
| Stonepine Capital Management, LLC | $122.597 | 30.122 | 0,16% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $122.128 | 30.007 | 0,16% | Aktien |
| Trexquant Investment LP | $121.030 | 29.737 | 0,16% | Aktien |
| STATE STREET CORP | $107.896 | 26.510 | 0,14% | Aktien |
| NORTHERN TRUST CORP | $105.165 | 25.839 | 0,14% | Aktien |
| Velan Capital Investment Management LP | $101.750 | 25.000 | 0,13% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $97.057 | 23.847 | 0,13% | Aktien |
| WealthTrust Asset Management, LLC | $83.093 | 20.416 | 0,11% | Aktien |
| Independent Advisor Alliance | $73.769 | 18.125 | 0,10% | Aktien |
| RBF Capital, LLC | $70.781 | 17.391 | 0,09% | Aktien |
| Quadrature Capital Ltd | $67.265 | 16.527 | 0,09% | Aktien |
| GOLDMAN SACHS GROUP INC | $65.340 | 16.054 | 0,09% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $64.991 | 15.958 | 0,09% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57.879 | 14.221 | 0,08% | Aktien |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $50.875 | 12.500 | 0,07% | Aktien |
| Sigma Planning Corp | $41.380 | 10.167 | 0,05% | Aktien |
| FMR LLC | $31.770 | 7.806 | 0,04% | Aktien |
| Tower Research Capital LLC (TRC) | $10.419 | 2.560 | 0,01% | Aktien |
| Steward Partners Investment Advisory, LLC | $9.015 | 2.215 | 0,01% | Aktien |
| Vanguard Global Advisers, LLC | $2.951 | 725 | 0,00% | Aktien |
| BARCLAYS PLC | $1.233 | 303 | 0,00% | Aktien |
| Strengthening Families & Communities, LLC | $1.091 | 268 | 0,00% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $212 | 52 | 0,00% | Aktien |
| JPMORGAN CHASE & CO | $211 | 50 | 0,00% | Aktien |
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC, Srinivas Akkaraju ×4 Einreichungen | 22. Mai 2026 | 54,20% | Änderung | · | SEC |
| ElevateBio, LLC (2) | 5. August 2022 | · | Erste Einreichung | · | SEC |
| F2 MG Ltd. (2), F2-TPO Investments, LLC (2), F2 MC, LLC (2), F2 Capital I 2020 LLC (2), F2 Bioscience AV 2022 LLC (2), Globeways Holdings Ltd. (2), Globeways Holdings II Ltd. (2), Morana Jovan-Embiricos (2) | 5. August 2022 | · | Erste Einreichung | · | SEC |
| ElevateBio LLC (2) | 13. August 2020 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 32 Insider · 14 Führungskräfte · 20 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Andrew Oxtoby | President and Chief Executive Officer | 19. März 2026 A | · | 0 | 0 | $0 |
| Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | 21. Februar 2025 S | 49.129 | 0 | 0 | $0 |
| Diana Brainard | Chief Executive Officer | 19. November 2024 S | 723.363 | 0 | 0 | $0 |
| Liisa Ann Bayko | Chief Financial Officer | 20. Juli 2026 A | · | 0 | 0 | $0 |
| Matthew Gall | Chief Financial Officer | 19. März 2026 A | · | 0 | 0 | $0 |
| Amy O'Leary Vandekop | VP, Corporate Controller | 27. August 2026 A | · | 0 | 0 | $0 |
| Matthew Feinsod | Chief Medical Officer | 19. März 2026 A | 4.030 | 0 | 0 | $0 |
| Brett R Hagen | Chief Accounting Officer | 19. März 2026 A | 0 | 0 | 1 | $-12.869 |
| Edward Miller | General Counsel | 21. Februar 2025 S | 6.517 | 0 | 0 | $0 |
| Cintia Piccina | Chief Commercial Officer | 3. Juli 2023 A | 147.000 | 0 | 0 | $0 |
| Ann M. Leen | Chief Scientific Officer | 2. Februar 2023 A | 124.006 | 0 | 0 | $0 |
| Jeroen B Van Beek | Chief Commercial Officer | 16. November 2022 S | 333.726 | 0 | 0 | $0 |
| Ercem Atillasoy | This Form 4/A is being filed correct the transaction dates reported in the original Form 4 filed on October 24, 2022. Officer T | 21. Oktober 2022 S | 131.372 | 0 | 0 | $0 |
| Agustin Melian | Chief Medical Officer | 4. Oktober 2021 S | 453.529 | 0 | 0 | $0 |
| Laurie Keating | Direktor | 1. August 2026 A | · | 0 | 0 | $0 |
| Napoleone Ferrara | Direktor | 3. Juni 2026 A | 504.000 | 0 | 0 | $0 |
| Michael Dybbs | Direktor | 3. Juni 2026 A | · | 0 | 0 | $0 |
| Morana Jovan-Embiricos | Direktor | 3. Juni 2026 A | 100.197 | 0 | 0 | $0 |
| David Hallal | Direktor | 3. Juni 2026 A | 2.143.662 | 0 | 0 | $0 |
| Anthony P Adamis | Direktor | 3. Juni 2026 A | · | 0 | 0 | $0 |
| Srinivas Akkaraju | Direktor | 3. Juni 2026 A | 11.444.503 | 0 | 0 | $0 |
| Leone D Patterson | Direktor | 3. Juni 2026 A | · | 0 | 0 | $0 |
| Samir Chandrakant Patel | Direktor | 10. April 2025 A | 100.800 | 0 | 0 | $0 |
| Derek N. Adams | Direktor | 6. Juni 2024 A | 70.000 | 0 | 0 | $0 |
| Malcolm Brenner | Direktor | 6. Juni 2024 A | 100.197 | 0 | 0 | $0 |
| Juan Vera | Direktor | 6. Juni 2024 A | 2.409.928 | 0 | 0 | $0 |
| Shawn Tomasello | Direktor | 6. Juni 2024 A | 70.000 | 0 | 0 | $0 |
| Jeffrey S Bornstein | Direktor | 6. Juni 2024 A | 110.197 | 0 | 0 | $0 |
| ElevateBio, LLC | Direktor | 28. Juli 2022 A | 16.674.766 | 0 | 0 | $0 |
| ANSBERT GADICKE | Direktor | 28. Juli 2022 A | 16.674.766 | 0 | 0 | $0 |
| John Robert Wilson | Direktor | 25. Mai 2021 A | 3.164.954 | 0 | 0 | $0 |
| Gilead Sciences, Inc. | 10%-Eigentümer | 27. Juni 2023 P | 16.635.286 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 5 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IWC · iShares Trust | 0,01% | 25.753 SH | 11. September 2026 | Täglich |
| DCOR · Dimensional ETF Trust | 0,00% | 3.296 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 137.373 SH | 19. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 255.337 SH | 19. August 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,00% | 2.614 NS | 31. Juli 2026 | N-PORT |
KLRS Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 14 Analysten
KAUF
Median-Ziel
$20.00
+640,7%
6 42,9%
Starker Kauf
6 42,9%
Kauf
2 14,3%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
7 Analysten · 2026-09-30Mittelwert-Ziel $18.71 +593,1%
← Unter allen Zielen
Aktueller Preis $2.70
Tief$7.00
Mittelwert$18.71
Hoch$25.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| KLRS | $193M | -3.0 | · | · | -65.8% | · |
| INKT | · | -3.8 | 4.5% | -6931.8% | 63.4% | · |
| FRMM | · | · | · | -6881.3% | -368.1% | · |
| ACET | · | -0.5 | · | · | · | · |
| BOLD | $27M | -0.5 | · | · | -46.7% | · |
| CNTB | $159M | -2.8 | -99.8% | -86687.5% | -97.9% | · |
| CLNN | $64M | · | -41.5% | -13086.5% | 200.2% | · |
| EXOZ | $92M | -10.0 | · | · | -172.3% | · |
| XLO | $3M | -0.2 | 589.9% | -80.0% | -165.5% | · |
| INMB | $41M | -0.8 | 257.1% | -91866.0% | -175.3% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 11, 2026